• 5th Floor. Amrita Tower, KPCC Junction, MG Road Kochi
  • Good Health and Hope
    Passionate about our commitment to provide breakthrough therapy.
    Know More
  • 5 New Chemical Entities
    And 12 Unmet Medical Conditions
    Breakthrough Research - will lead to better drugs and therapeutics
    Know More
  • PNB 001 and COVID 19
    PNB 001 is in the Phase 3 Clinical Trials in Covid 19 Patients.
    Know More

PNB Vesper, focused on developing drugs for unmet medical needs

PNB Vesper Life Sciences Pvt. Ltd is a research-based pharmaceutical organization that is determined to discover drugs for serious diseases and unmet medical conditions. PNB Vesper is currently one of very few companies in India focusing only on research-based NCEs, rather than generics. The company based in Kochi, India was incorporated in the year 2011. The company’s promoters have been contracting its NCE synthesis and related research and development activities, preclinical and clinical studies with various reputed academic and commercial organizations in the UK, US, Thailand, and India for the last 14 years (even before incorporating PNB Vesper Life Science in 2011).

Our Core Values

We believe that there are no limits to what we can accomplish as a Research company and are always willing to explore new ideas and forward-thinking in our Research. Our strength is the commitment of our team. We work together in support of one another to achieve the company’s goals and objectives. We support continuous efforts that lead to the discovery of new molecules for unmet diseases, improvements in the processes and products.

  • Passionate about our commitment to provide breakthrough therapy
  • Nurture a positive Global environment and setting a model for others to follow.
  • Breakthrough technology that will lead to better drugs and therapeutics.
  • Value our customers (patients) and stake holders with utmost respect.
  • Excellence in quality and in everything we do.
  • Seek new areas to innovate and grow.
  • Profitable and sustainable growth.
  • Ethics in every step of our way.
  • Respect our partners and associates..

100 +

Years of Research
Experience

Our Core Values

Our Research Molecules

PNB Vesper is focused to develop cost effective drugs for unmet medical needs. We have synthesized hundreds of molecules and systematically characterized to select the lead molecules. The lead molecules have the potential to treat variety of diseases including Covid 19, Inflammatory Pain, Different kinds of Cancer's, Inflammatory bowel disease (IBD), Neurological diseases such as Anxiety, Depression, Metabolic diseases and others.
PNB VESPER ON

Publications

PNB Vesper Life Sciences Pvt. Ltd is a research-based bio-pharmaceutical organization that is determined to discover drugs for serious diseases and unmet medical conditions. PNB Vesper is currently one of very few companies in India.

Recent News and Media Coverages

Our research is widely covered by various media's domestically and internationally through the print and electronic mediums.
Balacovin: Kerala firm PNB Vesper Life gets nod for phase 3 clinical trial of Covid drug

A Covid-19 drug manufactured by Kerala-based company, PNB Vesper, has received nod by DCGI to conduct Phase 3 clinical trials. The company will be conducting a nationwide multi-centred clinical trial of the drug- PNB-001 (GPP-BALACOVIN), on Covid-19 patients who are … Continued

READ MORE
PNB Vesper gets DCGI nod to conduct Ph III trials on COVID-19 drug

Kerala-based pharmaceutical organization PNB Vesper has received DCGI permission to conduct the final phase 3 clinical trials. After a detailed deliberation by the Subject Expert Committee (SEC) on the Phase 2 Clinical Trial results of PNB-001 (GPP-BALACOVIN), the company has … Continued

READ MORE
PNB Vesper gets DCGI nod to begin phase III trials for PNB 001/GPP-Balacovin for Covid-19 treatment

PNB Vesper, a leading Kerala-based life sciences company received permission from the DCGI and entering into the final phase 3 clinical trials. After a detailed deliberation by the Subject Expert Committee (SEC) on the phase 2 clinical trial results of … Continued

READ MORE